CD274 and neoplasm: Endpoints included progression-free survival (PFS) and overall survival (OS), stratified by PD-L1 tumor proportion score (TPS) (< 50% vs. ≥ 50%), treatment duration, and treatment line.<h4>Results</h4>Of 354 patients, 52 (15%) long-term responders were identified for analysis.